期刊
CLINICAL IMMUNOLOGY
卷 142, 期 1, 页码 68-75出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2011.05.009
关键词
Cladribine; Multiple sclerosis; Immunosuppressant; Oral drugs
类别
资金
- Walter and Ilse Rose-Stiftung
- German Ministry for Education and Research (BMBF) [01GI1002]
- ECTRIMS (European Conference on Research and Treatment of MS)
There is an unmet need for more potent and convenient drugs in the treatment of patients diagnosed with multiple sclerosis (MS). Among five currently investigated oral drugs with an ongoing or completed phase III program, promising efficacy data for oral cladribine have recently been published. However, benefits need to be weighed against potential risks to define the role of this compound within current treatment regimens. Here we review present data on efficacy of oral cladribine and discuss known and anticipated risks of this drug. (C) 2011 Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据